July brings the first stock market listing of 2026 on the Casablanca Stock Exchange, with shares in T2S Holding Group going public after the Moroccan Capital Market Authority (AMMC) granted its approval through visa No. VI/EM/021/2026.
Through the initial public offering, with an expected total value exceeding one billion dirhams — 1,099,999,682 dirhams to be exact — the group aims to raise the financial resources needed to support its growth plans and develop its investment activities by 2030.
The IPO is split into two complementary tranches. The first involves a capital increase through the issuance of new shares allocated to the public, worth 349,999,838 dirhams including the issue premium. The second rests on the sale of existing shares offered to the public on the exchange, worth up to 749,999,844 dirhams, according to the figures announced after the market regulator’s approval.
The listing price has been set at 223 dirhams per share. The subscription period runs from Monday, July 13 through Friday, July 17 at 3:30 p.m. The shares on offer will be available for purchase throughout that window across all bank agency networks and the brokerage firms belonging to the financial placement syndicate.
T2S Holding Group, a leading player in medical technology, was founded in 1992 and operates in the integrated medical technology (MedTech) sector. Its activities span the import, distribution and maintenance of high-tech medical equipment, the industrial production of radiopharmaceuticals, and the development of software and digital health systems. The group currently employs 418 people and runs a central logistics platform in Casablanca, while its services and equipment cover the needs of health institutions in Morocco and in more than twenty African countries.
The group’s mission is to equip healthcare professionals with the world’s most advanced technologies, in both diagnosis and treatment, by delivering solutions that are clinically effective for patients and doctors and sustainable within the health system.
Drawing on 35 years of accumulated experience, the group has established itself as a benchmark Moroccan player in integrated medical technology.
It has built its position across seven high-value-added business lines: medical examination and imaging and oncology; operating theatre equipment and hospital treatments; medical supplies; laboratory diagnostics (lab equipment, reagents and molecular biology solutions); the production and distribution of radiopharmaceuticals; the distribution of contrast media for diagnostic imaging and health products for nuclear medicine; and medical digital systems (IT solutions for health institutions and after-sales services covering equipment installation, maintenance and technical support).
The group has made no secret that its strategic vision for the coming years rests on four main pillars: consolidating its historic position in its current activities; offering new and complementary categories of advanced products and technological solutions; expanding its international presence, particularly in Africa; and pursuing a strategy of external growth through targeted acquisitions. The listing, in particular, is intended to enable the group to realize its strategy and ambitions.
The operation’s prospectus, approved by the AMMC, comprises the transaction note on the listing of T2S Holding Group’s shares on the exchange and the group’s reference document for the 2025 financial year.
